EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKohortenstudieOpen Access · CC BY-NC 4.0

Pharmacogenomics-Guided Precision Therapy for Chronic Kidney Disease with Resistant Hypertension: A Prospective Cohort Study

XiaoWen Ha, XiYuan Gao, Wei Teng, JiaLi Zhang, Zuolamu Maimaiti, Dilina Yalikun, ShuFen Yang, Lu Bai, Takexi Caoke, Hong Jiang

Kidney and Blood Pressure Research · 2025

DOI: 10.1159/000549936 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Kidney and Blood Pressure Research, 2025. Verfasst von XiaoWen Ha und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China. Hauptthemen laut MEDLINE: Hypertension, Renal Insufficiency, Chronic, Antihypertensive Agents, Precision Medicine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Managing blood pressure in patients with chronic kidney disease (CKD) complicated by resistant hypertension (RH) remains a major clinical challenge. The clinical utility of pharmacogenomics (PGx) in this high-risk population has not been well established. This study aimed to evaluate the effectiveness of PGx-guided precision therapy on blood pressure control, medication optimization, and treatment safety in CKD patients with RH.

Methods

A single-center prospective cohort study was conducted using the Yidu Cloud big data platform at People’s Hospital of Xinjiang Uygur Autonomous Region. Sixty-five patients with CKD and RH were enrolled and randomized into either an empirical treatment group (Empirical group, n = 22) or a PGx-guided group (PGx group, n = 43). Patients in the PGx group received individualized therapy based on genetic testing covering 21 antihypertensive drugs, whereas the Empirical group received conventional empirical treatment. The primary endpoint was the rate of achieving target blood pressure (systolic BP

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionRenal Insufficiency, ChronicAntihypertensive AgentsPrecision MedicinePharmacogeneticsHumansProspective StudiesMaleFemaleMiddle AgedAgedCohort StudiesBlood Pressure

Stichwörter der Autor:innen

Adverse eventsChronic kidney diseasePharmacogenomicsPrecision therapyResistant hypertension

Substanzen

Antihypertensive Agents

Autor:innen und Institutionen

  • Division of Nephrology, Department of Internal Medicine, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
  • Department of Pharmacy, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
  • Division of Nephrology, Department of Internal Medicine, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China, jangh-yt@163.com.

Zitieren

APA

Ha, X., Gao, X., Teng, W., Zhang, J., Maimaiti, Z., Yalikun, D., Yang, S., Bai, L., Caoke, T., & Jiang, H. (2025). Pharmacogenomics-Guided Precision Therapy for Chronic Kidney Disease with Resistant Hypertension: A Prospective Cohort Study. Kidney and Blood Pressure Research. https://doi.org/10.1159/000549936

Vancouver

Ha X, Gao X, Teng W, Zhang J, Maimaiti Z, Yalikun D, et al. Pharmacogenomics-Guided Precision Therapy for Chronic Kidney Disease with Resistant Hypertension: A Prospective Cohort Study. Kidney and Blood Pressure Research. 2025. doi:10.1159/000549936

BibTeX
@article{Ha2025,
  author = {Ha, XiaoWen and Gao, XiYuan and Teng, Wei and Zhang, JiaLi and Maimaiti, Zuolamu and Yalikun, Dilina and Yang, ShuFen and Bai, Lu and Caoke, Takexi and Jiang, Hong},
  title = {Pharmacogenomics-Guided Precision Therapy for Chronic Kidney Disease with Resistant Hypertension: A Prospective Cohort Study},
  journal = {Kidney and Blood Pressure Research},
  year = {2025},
  doi = {10.1159/000549936}
}
Kostenlos starten →